Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 4/2017

01-12-2017 | Family Planning (A Burke, Section Editor)

Postpartum LARC: Best Practices, Policy and Public Health Implications

Authors: Erryn Tappy, Roxanne Jamshidi

Published in: Current Obstetrics and Gynecology Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

To review current literature highlighting effective strategies and policies in implementation of postpartum long-acting reversible contraception (LARC) as well as outcomes of postpartum LARC use.

Recent Findings

The use of postpartum LARC is highly desired by patients, effective at reducing rates of unintended and short interval pregnancies, and has demonstrated significant health care savings. Despite these positive outcomes associated with postpartum LARC use, availability of immediate postpartum LARC is limited in the majority of US hospitals. Barriers to the provision of postpartum LARC include lack of physician education and comfort in placing postpartum LARC, lack of effective reimbursement structures, lack of streamlined protocols for identifying women who are candidates for postpartum LARC, and lack of structural support for the provision of LARC.

Summary

Providers can eliminate barriers to postpartum LARC access once patients are discharged from the hospital by enhancing efforts to identify patients who are at high risk of no follow-up and by eliminating two-step protocols for LARC insertion. A step-wise strategical approach involving planning, implementation, and sustainability is effective for initiating postpartum LARC programs in hospitals. Enhancing physician education, collaborating among hospital-wide stakeholders, and reforming reimbursement strategies are all key components of successful implementation plans. Future research should continue to demonstrate cost effectiveness of postpartum LARC, and efforts to disseminate this information to other hospitals should be enhanced. Research should also target postpartum LARC insertion techniques to overcome variability of expulsion rate data and elucidate superior postpartum insertion techniques. Lastly, research should target identification strategies for women who desire postpartum LARC; for example, protocol development for streamlining access to patient’s contraceptive preferences from antenatal care to labor and delivery care, or a modified labor and delivery intake form.
Literature
1.
Goldthwaite LM, Shaw KA. Immediate postpartum provision of long-acting reversible contraception. Curr Opin Obstet Gynecol. 2015;27(6):460–4.PubMed
2.
Braniff K, Gomez E, Muller RA. Randomised clinical trial to assess satisfaction with the levonorgestrel-releasing intrauterine system inserted at caesarean section compared to postpartum placement. Aust N Z J Obstet Gynaecol. 2015;55(3):279–83.PubMedPubMedCentralCrossRef
3.
Celen S, Moroy P, Sucak A, Aktulay A, Danisman N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. Contraception. 2004;69(4):279–82.PubMedCrossRef
4.
White K, Teal SB, Potter JE. Contraception after delivery and short interpregnancy intervals among women in the United States. Obstet Gynecol. 2015;125(6):1471–7.PubMedPubMedCentralCrossRef
5.
Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA. 2006;295(15):1809–23.PubMedCrossRef
6.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184–96.CrossRef
7.
Prager SW, McCoy EE. Immediate postpartum intrauterine contraception insertion. Obstet Gynecol Clin N Am. 2015;42(4):569–82.CrossRef
8.
Damle LF, Gohari AC, McEvoy AK, Desale SY, Gomez-Lobo V. Early initiation of postpartum contraception: does it decrease rapid repeat pregnancy in adolescents? J Pediatr Adolesc Gynecol. 2015;28(1):57–62.PubMedCrossRef
9.
Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.PubMedPubMedCentralCrossRef
10.
O'Neil-Callahan M, Peipert JF, Zhao Q, Madden T, Secura G. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122(5):1083–91.PubMedCrossRef
11.
Lester F, Kakaire O, Byamugisha J, Averbach S, Fortin J, Maurer R, et al. Intracesarean insertion of the Copper T380A versus 6 weeks postcesarean: a randomized clinical trial. Contraception. 2015;91(3):198–203.PubMedCrossRef
12.
Washington CI, Jamshidi R, Thung SF, Nayeri UA, Caughey AB, Werner EF. Timing of postpartum intrauterine device placement: a cost-effectiveness analysis. Fertil Steril. 2015;103(1):131–7.PubMedCrossRef
13.
14.
Dahlke JD, Terpstra ER, Ramseyer AM, Busch JM, Rieg T, Magann EF. Postpartum insertion of levonorgestrel—intrauterine system at three time periods: a prospective randomized pilot study. Contraception. 2011;84(3):244–8.PubMedCrossRef
15.
Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev. 2015;6:CD003036.
16.
Bonilla Rosales F, Aguilar Zamudio ME, Cazares Montero Mde L, Hernandez Ortiz ME, Luna Ruiz MA. Factors for expulsion of intrauterine device Tcu380A applied immediately postpartum and after a delayed period. Rev Med Inst Mex Seguro Soc. 2005;43(1):5–10.PubMed
17.
Bryant AG, Bauer AE, Stuart GS, Levi EE, Zerden ML, Danvers A, et al. Etonogestrel-releasing contraceptive implant for postpartum adolescents: a randomized controlled trial. J Pediatr Adolesc Gynecol. 2016;30(3):389–94.PubMedCrossRef
18.
Woo I, Seifert S, Hendricks D, Jamshidi RM, Burke AE, Fox MC. Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devices. Contraception. 2015;92(6):532–5.PubMedCrossRef
19.
Levi EE, Stuart GS, Zerden ML, Garrett JM, Bryant AG. Intrauterine device placement during cesarean delivery and continued use 6 months postpartum: a randomized controlled trial. Obstet Gynecol. 2015;126(1):5–11.PubMedPubMedCentralCrossRef
20.
Cohen R, Sheeder J, Arango N, Teal SB, Tocce K. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices. Contraception. 2016;93(2):178–83.PubMedCrossRef
21.
•• American College of Obstetricians and Gynecologists. Committee opinion No. 670: immediate postpartum long-acting reversible contraception. Obstet Gynecol. 2016;128(2):e32–7. ACOG’s summary of evidence supporting the provision of immediate postpartum LARC. Strategies to implement postpartum LARC programs are also discussed. Also, refer to ACOG’s online support: www.​acog.​org/​LARCImmediatePos​tpartum CrossRef
22.
Dragoman MV, Jatlaoui T, Nanda K, Curtis KM, Gaffield ME. Research gaps identified during the 2014 update of the WHO medical eligibility criteria for contraceptive use and selected practice recommendations for contraceptive use. Contraception. 2016;94(3):195–201.PubMedCrossRef
23.
Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.CrossRef
24.
Zerden ML, Tang JH, Stuart GS, Norton DR, Verbiest SB, Brody S. Barriers to receiving long-acting reversible contraception in the postpartum period. Womens Health Issues. 2015;25(6):616–21.PubMedCrossRef
25.
Holland E, Michelis LD, Sonalkar S, Curry CL. Barriers to immediate post-placental intrauterine devices among attending level educators. Womens Health Issues. 2015;25(4):355–8.PubMedCrossRef
26.
Conti J, Shaw K. Update on long-acting reversible methods. Curr Opin Obstet Gynecol. 2015;27(6):471–5.PubMed
27.
Lotke PS. Increasing use of long-acting reversible contraception to decrease unplanned pregnancy. Obstet Gynecol Clin N Am. 2015;42(4):557–67.CrossRef
28.
Harney C, Dude A, Haider S. Factors associated with short interpregnancy interval in women who plan postpartum LARC: a retrospective study. Contraception. 2017;95(3):245–50.PubMedCrossRef
29.
Bergin A, Tristan S, Terplan M, Gilliam ML, Whitaker AKA. Missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception. 2012;86(6):694–7.PubMedCrossRef
30.
Bryant AS, Haas JS, McElrath TF, McCormick MC. Predictors of compliance with the postpartum visit among women living in healthy start project areas. Matern Child Health J. 2006;10(6):511–6.PubMedCrossRef
31.
Baldwin MK, Edelman AB, Lim JY, Nichols MD, Bednarek PH, Jensen JT. Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial. Contraception. 2016;93(4):356–63.PubMedCrossRef
32.
Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010;116(5):1079–87.PubMedPubMedCentralCrossRef
33.
34.
Xu JX, Rivera R, Dunson TR, Zhuang LQ, Yang XL, Ma GT, et al. A comparative study of two techniques used in immediate postplacental insertion (IPPI) of the Copper T-380A IUD in Shanghai, People’s Republic of China. Contraception. 1996;54(1):33–8.PubMedCrossRef
35.
36.
Hayes JL, Cwiak C, Goedken P, Zieman MA. Pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception. 2007;76(4):292–6.PubMedCrossRef
37.
Braga GC, Ferriolli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact. Contraception. 2015;92(6):536–42.PubMedCrossRef
38.
Hofler LG, Cordes S, Cwiak CA, Goedken P, Jamieson DJ, Kottke M. Implementing immediate postpartum long-acting reversible contraception programs. Obstet Gynecol. 2017;129(1):3–9.PubMedCrossRef
39.
Rankin KM, Kroelinger CD, DeSisto CL, Pliska E, Akbarali S, Mackie CN, et al. Application of implementation science methodology to immediate postpartum long-acting reversible contraception policy roll-out across states. Matern Child Health J. 2016;20(Suppl 1):173–9.PubMedPubMedCentralCrossRef
40.
Gariepy AM, Duffy JY, Xu X. Cost-effectiveness of immediate compared with delayed postpartum etonogestrel implant insertion. Obstet Gynecol. 2015;126(1):47–55.PubMedPubMedCentralCrossRef
41.
• Kroelinger CD, Waddell LF, Goodman DA, Pliska E, Rudolph C, Ahmed E, et al. Working with state health departments on emerging issues in maternal and child health: immediate postpartum long-acting reversible contraceptives. J Womens Health (Larchmt). 2015;24(9):693–701. Excellent summary of multi-disciplinary forum on policy development and implementation of providing postpartum LARC. Specific and practical pointers are given to address these challenges, including useful online resources. CrossRef
42.
Moniz MH, Chang T, Davis MM, Forman J, Landgraf J, Dalton VK. Medicaid administrator experiences with the implementation of immediate postpartum long-acting reversible contraception. Womens Health Issues. 2016;26(3):313–20.PubMedCrossRef
43.
Moniz MH, Dalton VK, Davis MM, Forman J, Iott B, Landgraf J, et al. Characterization of Medicaid policy for immediate postpartum contraception. Contraception. 2015;92(6):523–31.PubMedCrossRef
44.
Sundstrom B, Baker-Whitcomb A, DeMaria AL. A qualitative analysis of long-acting reversible contraception. Matern Child Health J. 2015;19(7):1507–14.PubMedCrossRef
45.
Rodriguez MI, Evans M, Espey E. Advocating for immediate postpartum LARC: increasing access, improving outcomes, and decreasing cost. Contraception. 2014;90(5):468–71.PubMedCrossRef
46.
Potter JE, Hubert C, White K. The availability and use of postpartum LARC in Mexico and among Hispanics in the United States. Matern Child Health J. 2017;21(9):1744–52.CrossRef
47.
Holland A, Watkins D. Flying start health visitors’ views of implementing the Newborn Behavioural Observation: barriers and facilitating factors. Community Pract. 2015;88(6):33–6.PubMed
48.
Goldthwaite LM, Sheeder J, Teal SB, Tocce KM. Comfort with skills and knowledge after immediate postpartum intrauterine device training. Obstet Gynecol. 2016;128(Suppl 1):6S–11S.PubMedCrossRef
49.
Thompson KM, Rocca CH, Kohn JE, Goodman S, Stern L, Blum M, et al. Public funding for contraception, provider training, and use of highly effective contraceptives: Aa cluster randomized trial. Am J Public Health. 2016;106(3):541–6.PubMedCrossRef
50.
• Moniz M, Chang T, Heisler M, Dalton VK. Immediate postpartum long-acting reversible contraception: the time is now. Contraception. 2016;95(4):335–8. Excellent review of implementation challenges to providing postpartum LARC. Specific and practical pointers are given to address these challenges, including useful online resources. PubMedCrossRef
51.
Singh S, Das V, Agarwal A, Dewan R, Mittal P, Bhamrah R, et al. A dedicated postpartum intrauterine device inserter: pilot experience and proof of concept. Glob Health Sci Pract. 2016;4(1):132–40.PubMedPubMedCentralCrossRef
52.
53.
54.
Sonfield A, Kost K, Gold RB, Finer LB. The public costs of births resulting from unintended pregnancies: national and state-level estimates. Perspect Sex Reprod Health. 2011;43(2):94–102.PubMedCrossRef
55.
Abma JC, Martinez GM, Copen CE. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, national survey of family growth 2006–2008. Vital Health Stat. 2010;23(30):1–47.
56.
Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to long-acting reversible contraceptive (LARC) use in adolescents. J Adolesc Health. 2013;52(4 Suppl):S59–63.PubMedCrossRef
Metadata
Title
Postpartum LARC: Best Practices, Policy and Public Health Implications
Authors
Erryn Tappy
Roxanne Jamshidi
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 4/2017
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-017-0225-z

Other articles of this Issue 4/2017

Current Obstetrics and Gynecology Reports 4/2017 Go to the issue

Urogynecology (S Pulliam and N Kohli, Section Editors)

Cognitive Impairment and Pelvic Floor Disorders

Urogynecology (S Pulliam and N Kohli, Section Editors)

Urodynamic Testing: Choosing Between Simple Versus Complex

Urogynecology (S Pulliam and N Kohli, Section Editors)

Urge Incontinence: Updates in Non-pharmacologic Treatments

Gynecologic Oncology (A Fader, Section Editor)

Uterine Sarcoma: Modern Treatment Paradigms

Urogynecology (S Pulliam and N Kohli, Section Editors)

Recurrent Urinary Tract Infection in Women

Urogynecology (S Pulliam and N Kohli, Section Editors)

Urogynecologic Care of the Transgender Patient